Human Drug Advisory Panel

The HDAP is comprised of a defined list of independent health professionals who are retained by the PMPRB under contract to potentially assist with scientific evaluations on an ad-hoc basis, as Staff may need, in view of their broad general knowledge of drug therapy, drug evaluation, drug utilization and clinical research methodology.

The HDAP currently has the following members:

• Dr. Bishal Gyawali, Associate Professor of Oncology at Queen’s University, Kingston, Ontario. Dr Gyawali’s research focuses on clinical trial designs and drug regulations, including health technology assessments and health economics, specially related to oncology.
• Dr. Muhammad Mamdani, Vice President – Data Science and Advanced Analytics at Unity Health Toronto, Director – Temerty Centre for Artificial Intelligence Research and Education in Medicine at the University of Toronto, and Professor in the Temerty Faculty of Medicine, Leslie Dan Faculty of Pharmacy, and Dalla Lana School of Public Health at the University of Toronto
• Dr. Peter Jamieson, Chief Medical Officer and Vice President Clinical Operations and Quality, Alberta Health Services.  Clinical Professor of Family Medicine at the University of Calgary.
• Dr. Michael Rieder, Professor with the Department of Paediatrics (with a cross-appointment to the Department of Physiology and Pharmacology) in the Faculty of Medicine and Dentistry at the University of Western Ontario in London and a Scientist in the Molecular Medicine Group at the Robarts Research Institute.  Dr. Rieder's research focus is on drug safety and optimal therapeutics in children as well as public policy on drug access and drug development for children.  Dr. Rieder's expertise includes paediatric pharmacology, clinical pharmacology, adverse drug reactions, drug safety, steroid biology and immunopharmacology
• Dr. Adil Virani, Clinical Associate Professor, Faculty of Pharmaceutical Sciences, UBC. He has overseen the pharmacy operations, both clinical and distribution of medications, at several large urban hospitals, community hospitals and a large outpatient facility in British Columbia.  He has also participated on several panels and advice programs for Canada’s Drug Agency.

For more information on the HDAP, please visit the Terms of Reference for the Human Drug Advisory Panel.